Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Poisoning

Free Subscription Articles published in J Hepatol Retrieve available abstracts of 31 articles: HTML format

Single Articles

September 2023
1. UZUN S, Zinner CP, Beenen AC, Alborelli I, et al
   Morphologic and molecular analysis of liver injury after SARS-CoV-2 vaccination reveals distinct characteristics.
   J Hepatol. 2023;79:666-676.
   PubMed     Abstract available
   
   
   August 2023
2. ROMA K, Mohammed S, Sieck B, Naik K, et al
   Kratom-induced acute liver injury: A case study and the importance of herbal supplement regulation.
   J Hepatol. 2023;79:581-584.
   PubMed     Abstract available
   
   
   May 2023
3. ANDRADE RJ, Aithal GP, de Boer YS, Liberal R, et al
   Nomenclature, Diagnosis and Management of Drug-induced Autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report.
   J Hepatol. 2023 May 8:S0168-8278(23)00320-3. doi: 10.1016/j.jhep.2023.
   PubMed     Abstract available
   
   
   
4. ZHANG CJ, Meyer SR, O'Meara MJ, Huang S, et al
   A human liver organoid screening platform for DILI risk prediction.
   J Hepatol. 2023;78:998-1006.
   PubMed     Abstract available
   
   
   
5. DALY AK, Bjornsson ES, Lucena MI, Andrade RJ, et al
   Drug-induced liver injury due to nitrofurantoin: Similar clinical features, but different HLA risk alleles in an independent cohort.
   J Hepatol. 2023;78:e165-e166.
   PubMed    
   
   
   March 2023
6. JAGADISAN B, Dhawan A
   Multidisciplinary approach and reactive immunosuppression for gene therapy related hepatotoxicity.
   J Hepatol. 2023 Mar 28:S0168-8278(23)00197-6. doi: 10.1016/j.jhep.2023.
   PubMed    
   
   
   
7. NOGUEIRAS R, Aspichueta P
   Expanding the roles of the renin-angiotensin system: Drug-induced liver injury.
   J Hepatol. 2023;78:457-459.
   PubMed    
   
   
   February 2023
8. CHALASANI N, Li YJ, Dellinger A, Navarro V, et al
   Clinical features, outcomes, and HLA risk factors associated with nitrofurantoin-induced liver injury.
   J Hepatol. 2023;78:293-300.
   PubMed     Abstract available
   
   
   November 2022
9. CHEN S, Lu Z, Jia H, Yang B, et al
   Hepatocyte-specific Mas activation enhances lipophagy and fatty acid oxidation to protect against acetaminophen-induced hepatotoxicity in mice.
   J Hepatol. 2022 Nov 9. pii: S0168-8278(22)03285.
   PubMed     Abstract available
   
   
   August 2022
10. BLACK SM, Zhang Z, Han Y, Zeng C, et al
    Reply to: "Protection against acetaminophen-induced liver injury with MG53: Muscle-liver axis and necroptosis".
    J Hepatol. 2022;77:562-563.
    PubMed    
    
    
    
11. BJORNSSON HK, Bjornsson ES
    Reply to: "Can azathioprine prevent infliximab-induced liver injury?"
    J Hepatol. 2022;77:555-556.
    PubMed    
    
    
    
12. JAESCHKE H, Umbaugh DS
    Protection against acetaminophen-induced liver injury with MG53: Muscle-liver axis and necroptosis.
    J Hepatol. 2022;77:560-562.
    PubMed    
    
    
    
13. MEUNIER L, Malezieux E, Bozon A, Meszaros M, et al
    Can azathioprine prevent infliximab-induced liver injury?
    J Hepatol. 2022;77:553-555.
    PubMed    
    
    
    May 2022
14. AHMAD J, Barnhart HX, Bonacini M, Ghabril M, et al
    Value of liver biopsy in the diagnosis of drug-induced liver injury.
    J Hepatol. 2022;76:1070-1078.
    PubMed     Abstract available
    
    
    April 2022
15. CHALASANI N, Bonkovsky HL, Stine JG, Gu J, et al
    Clinical characteristics of antiepileptic-induced liver injury in patients from the DILIN prospective study.
    J Hepatol. 2022;76:832-840.
    PubMed     Abstract available
    
    
    March 2022
16. XU L, Yang Y, Wen Y, Jeong JM, et al
    Hepatic recruitment of eosinophils and their protective function during acute liver injury.
    J Hepatol. 2022 Mar 5. pii: S0168-8278(22)00131.
    PubMed     Abstract available
    
    
    February 2022
17. GHALLAB A, Hassan R, Hofmann U, Friebel A, et al
    Interruption of bile acid uptake by hepatocytes after acetaminophen overdose ameliorates hepatotoxicity.
    J Hepatol. 2022 Feb 4. pii: S0168-8278(22)00062.
    PubMed     Abstract available
    
    
    
18. BJORNSSON ES, Andrade RJ
    Long-term sequelae of drug-induced liver injury.
    J Hepatol. 2022;76:435-445.
    PubMed     Abstract available
    
    
    January 2022
19. SHROFF H, Satapathy SK, Crawford JM, Todd NJ, et al
    Liver injury following SARS-CoV-2 vaccination: A multicenter case series.
    J Hepatol. 2022;76:211-214.
    PubMed    
    
    
    
20. BJORNSSON HK, Gudbjornsson B, Bjornsson ES
    Infliximab-induced liver injury: Clinical phenotypes, autoimmunity and the role of corticosteroid treatment.
    J Hepatol. 2022;76:86-92.
    PubMed     Abstract available
    
    
    November 2021
21. HAN Y, Black S, Gong Z, Chen Z, et al
    Membrane-delimited signaling and cytosolic action of MG53 preserve hepatocyte integrity during drug-induced liver injury.
    J Hepatol. 2021 Nov 1. pii: S0168-8278(21)02154.
    PubMed     Abstract available
    
    
    October 2021
22. FERNANDEZ-CHECA JC, Bagnaninchi P, Ye H, Sancho-Bru P, et al
    Advanced preclinical models for evaluation of drug-induced liver injury - consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET].
    J Hepatol. 2021;75:935-959.
    PubMed     Abstract available
    
    
    August 2021
23. TAVABIE OD, Karvellas CJ, Salehi S, Speiser JL, et al
    A novel microRNA-based prognostic model outperforms standard prognostic models in patients with acetaminophen-induced acute liver failure.
    J Hepatol. 2021;75:424-434.
    PubMed     Abstract available
    
    
    
24. ASHBY K, Zhuang W, Gonzalez-Jimenez A, Alvarez-Alvarez I, et al
    Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI.
    J Hepatol. 2021;75:333-341.
    PubMed     Abstract available
    
    
    July 2021
25. STEPHENS C, Robles-Diaz M, Medina-Caliz I, Garcia-Cortes M, et al
    Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry.
    J Hepatol. 2021;75:86-97.
    PubMed     Abstract available
    
    
    March 2021
26. MOZZANEGA B
    Ulipristal acetate and liver-injuries: while Esmya is revoked, EllaOne is allowed in repeated self-administrations possibly exceeding UPA toxic-dosing with Esmya.
    J Hepatol. 2021;74:750-751.
    PubMed    
    
    
    
27. CHAND D, Mohr F, McMillan H, Tukov FF, et al
    Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy.
    J Hepatol. 2021;74:560-566.
    PubMed     Abstract available
    
    
    February 2021
28. GUDD CL, Au L, Triantafyllou E, Shum B, et al
    Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis.
    J Hepatol. 2021 Feb 22. pii: S0168-8278(21)00108.
    PubMed     Abstract available
    
    
    
29. LIEBE R, Esposito I, Bock HH, Dahl SV, et al
    Diagnosis and management of secondary causes of steatohepatitis.
    J Hepatol. 2021 Feb 9. pii: S0168-8278(21)00096.
    PubMed     Abstract available
    
    
    May 2020
30. STATTERMAYER AF, Halilbasic E, Wrba F, Ferenci P, et al
    Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults.
    J Hepatol. 2020 May 3. pii: S0168-8278(20)30280.
    PubMed     Abstract available
    
    
    February 2019
31. MANCO R, Clerbaux LA, Verhulst S, Nader MB, et al
    Reactive cholangiocytes differentiate into proliferative hepatocytes with efficient DNA repair in mice with chronic liver injury.
    J Hepatol. 2019 Feb 19. pii: S0168-8278(19)30117.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Poisoning is free of charge.